- Home
- LGVN vs CVKD Comparison
LGVN vs CVKD Comparison
Compare LGVN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- CVKD
- Stock Information
- Founded
- LGVN 2014
- CVKD 2022
- Country
- LGVN United States
- CVKD United States
- Employees
- LGVN N/A
- CVKD N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- LGVN Health Care
- CVKD Health Care
- Exchange
- LGVN Nasdaq
- CVKD Nasdaq
- Market Cap
- LGVN 30.0M
- CVKD 17.1M
- IPO Year
- LGVN 2021
- CVKD 2023
- Fundamental
- Price
- LGVN $2.05
- CVKD $14.45
- Analyst Decision
- LGVN Strong Buy
- CVKD Strong Buy
- Analyst Count
- LGVN 2
- CVKD 2
- Target Price
- LGVN $8.00
- CVKD $52.50
- AVG Volume (30 Days)
- LGVN 393.9K
- CVKD 59.6K
- Earning Date
- LGVN 11-08-2024
- CVKD 11-08-2024
- Dividend Yield
- LGVN N/A
- CVKD N/A
- EPS Growth
- LGVN N/A
- CVKD N/A
- EPS
- LGVN N/A
- CVKD N/A
- Revenue
- LGVN $1,229,000.00
- CVKD N/A
- Revenue This Year
- LGVN $161.78
- CVKD N/A
- Revenue Next Year
- LGVN $8.62
- CVKD N/A
- P/E Ratio
- LGVN N/A
- CVKD N/A
- Revenue Growth
- LGVN 39.34
- CVKD N/A
- 52 Week Low
- LGVN $0.77
- CVKD $5.40
- 52 Week High
- LGVN $23.90
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- LGVN 52.20
- CVKD 56.80
- Support Level
- LGVN $1.76
- CVKD $11.19
- Resistance Level
- LGVN $2.26
- CVKD $17.95
- Average True Range (ATR)
- LGVN 0.12
- CVKD 1.37
- MACD
- LGVN 0.05
- CVKD 0.10
- Stochastic Oscillator
- LGVN 58.00
- CVKD 49.64
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.